PAX1/JAM3双基因甲基化用于ASC H以下HR HPV感染患者宫颈高级别病变风险分层的研究

李 想
河南中医药大学第五临床医学院/郑州人民医院病理科

摘要


目的：探讨PAX1/JAM3双基因甲基化对细胞学为ASC H以下HR HPV感染患者发生宫颈高级别病变
（CIN2+）的风险分层价值。方法：采用回顾性研究方法，收集2024年8月-2026年1月于郑州人民医院就诊，细胞
学结果为ASC H以下的HR HPV阳性患者共167例。根据HPV亚型分为HPV16/18阳性组与非HPV16/18阳性组，分
析PAX1/JAM3双基因甲基化检测的结果与CIN2+的相关性，并计算出相应的灵敏度、特异度、PPV、NPV及AUC。
结果：在HPV16/18阳性组，甲基化阳性与CIN2+存在显著相关（P<0.05），灵敏度67.86%，特异度90.00%，PPV
79.17%，NPV 83.33%，AUC=0.79；在非HPV16/18阳性亚组，甲基化阳性与CIN2+病变无统计学关联（P>0.05），
灵敏度37.50%，特异度79.45%，PPV 28.57%，NPV 85.29%，AUC=0.59。结论：在ASC-H以下人群中，PAX1/JAM3
双基因甲基化的风险分层价值存在HPV亚型依赖性，其在HPV16/18阳性人群中具有较好应用价值，但不建议在非
16/18高危HPV感染者的风险分层中单独应用；甲基化阴性不能完全排除宫颈高级别病变，临床需结合其他检查综
合决策。

关键词


HPV;宫颈癌;PAX1/JAM3双基因甲基化

全文:

PDF


参考


[1]Skręt A, Trawińska J, Bielatowicz J, et al. Synchronous occurrence of HPV-associated cervical squamous cell carcinoma (FIGO IIA) in prolapsed uterus and adenocarcinoma of the anal canal cT1N0M0: Case report [J]. Medicine (Baltimore), 2021, 100(50): e28004.http://doi. org/10.1097/md.0000000000028004.

[2]Bouvard V, Baan R, Straif K, et al. A review of human carcinogens--Part B: biological agents [J]. Lancet Oncol, 2009, 10(4): 321-322.http://doi.org/10.1016/s1470- 2045(09)70096-8.

[3]Walboomers J M, Jacobs M V, Manos M M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide [J]. J Pathol, 1999, 189(1): 12-19.http:// doi.org/10.1002/(sici)1096-9896(199909)189:1<12::Aidpath431>3.0.Co;2-f.

[4]周晖，刘昀昀，毕卓菲，等.《国际妇产科联盟 （FIGO）2025癌症报告：子宫颈癌诊治指南》解读[J].中国实用妇科与产科杂志，2026，42（6）：628-635. http： //doi.org/10.19538/j.fk2026060112.

[5]陈贞，史姝男，胡阿锦.PAX1/JAM3基因甲基化检测对宫颈高级别鳞状上皮内病变的预测价值[J].临床与实验病理学杂志，1-12[2026-08-23]. https：//link.cnki. net/urlid/34.1073.R.20260821.1103.002.

[6]Koliopoulos G, Nyaga V N, Santesso N, et al. Cytology versus HPV testing for cervical cancer screening in the general population [J]. Cochrane Database Syst Rev, 2017, 8(8): Cd008587.http://doi.org/10.1002/14651858. CD008587.pub2.

[7]Peng H, Li J, Zhou Q, et al. Enhanced diagnostic accuracy of high-grade cervical intraepithelial neoplasia in postmenopausal women through PAX1/JAM3 methylation analysis [J]. Int J Cancer, 2026, 158(4): 1116-1125.http://doi. org/10.1002/ijc.70245.

[8]中 国 中 西 医 结 合 学 会 检 验 医 学 专 业 委 员 会， 等.子宫颈癌PAX1联合JAM3双基因甲基化检测流程、 报告及临床应用专家共识[J].中华检验医学杂志，2025， 48（2）：192-200.

[9]McCluggage W G, Singh N, Gilks C B. Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020) [J]. Histopathology, 2022, 80(5): 762-778.http://doi. org/10.1111/his.14609.

[10]Lin S, Gao K, Gu S, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years [J]. Cancer, 2021, 127(21): 4030-4039. http://doi.org/10.1002/cncr.33795.

[11]Zhang J, Wang H, Liu Y, et al. HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China [J]. J Clin Microbiol, 2026, 64(3): e0128925.http://doi. org/10.1128/jcm.01289-25.

[12]Cuschieri K S, Whitley M J, Cubie H A. Human papillomavirus type specific DNA and RNA persistence-- implications for cervical disease progression and monitoring [J]. J Med Virol, 2004, 73(1): 65-70.http://doi.org/10.1002/ jmv.20062.

[13]Stoler M H, Wright T C, Jr., Cuzick J, et al. APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results [J]. Am J Obstet Gynecol, 2013, 208(2): 144.e141-148. http://doi.org/10.1016/j.ajog.2012.12.003.

[14]Fei J, Zhai L, Wang J, et al. Evaluating PAX1/JAM3 methylation for triage in HPV 16/18-infected women [J]. Clin Epigenetics, 2024, 16(1): 190.http://doi.org/10.1186/ s13148-024-01804-w.


Refbacks

  • 当前没有refback。